Invention Grant
- Patent Title: CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
-
Application No.: US16347743Application Date: 2017-11-08
-
Publication No.: US11883430B2Publication Date: 2024-01-30
- Inventor: Shikhar Mehrotra , Shilpak Chatterjee
- Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
- Applicant Address: US SC Charleston
- Assignee: MUSC Foundation for Research Development
- Current Assignee: MUSC Foundation for Research Development
- Current Assignee Address: US SC Charleston
- Agency: Parker Highlander PLLC
- International Application: PCT/US2017/060537 2017.11.08
- International Announcement: WO2018/089423A 2018.05.17
- Date entered country: 2019-05-06
- Main IPC: A61K35/17
- IPC: A61K35/17 ; A61P35/00 ; A61K35/26 ; C07K16/24 ; C12N5/0783 ; A61K45/06 ; A61K9/00 ; C07K16/28 ; C07K16/30 ; A61K39/395
Abstract:
The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
Public/Granted literature
- US20190255111A1 CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY Public/Granted day:2019-08-22
Information query
IPC分类:
